Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
NewTimeSpace News: On 15 July 2026, Ascletis Pharma(01672.HK) issued an announcement that the Company has selected the fixed-dose combination of ASC48 and ASC30 (ASC30_48 FDC) for clinical development.
The Company plans to file an IND application for oral ASC30_48 FDC tablets with the FDA in the fourth quarter of 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
- WEIGAO GROUP(01066.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 774.12 million, YoY decrease of 23.23%
- WK GROUP (02535.HK): Appoints Shousheng Capital as Independent Financial Adviser to Advise on Fairness and Reasonableness of the Offer
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
